The gut microbiota produce hundreds of molecules that are present at high concentrations 31 in circulation and whose levels vary widely among humans. In most cases, molecule production 32 has not been linked to specific bacterial strains or metabolic pathways, and unraveling the 33 contribution of each molecule to host biology remains difficult. A general system to 'toggle' 34 molecules in this pool on/off in the host would enable interrogation of the mechanisms by which 35 they modulate host biology and disease processes. Such a system has been elusive due to 36 limitations in the genetic manipulability of Clostridium and its relatives, the source of many 37 molecules in this pool. Here, we describe a method for reliably constructing clean deletions in a 38 model commensal Clostridium, C. sporogenes (Cs), including multiply mutated strains. We 39 demonstrate the utility of this method by using it to 'toggle' off the production of ten Cs-derived 40 molecules that accumulate in host tissues. By comparing mice colonized by wild-type Cs versus a 41 mutant deficient in the production of branched short-chain fatty acids, we discover a previously 42 unknown IgA-modulatory activity of these abundant microbiome-derived molecules. Our method 43 opens the door to interrogating and sculpting a highly concentrated pool of chemicals from the 44 microbiome. 45 3
guide RNA (gRNA), and a 1.5-2.5 kb repair template and transferred it by conjugation into Cs. However, 134
we did not obtain viable colonies, even after multiple rounds of vector design modifications (see 135
Supplementary Text for more detail). 136
Having observed that the conjugation efficiency for Cs is greatly diminished for plasmids >10 kb, 137 we redesigned the system by splitting its components into two separate vectors: one that contains the 138 gRNA and repair template, and another that harbors Cas9 under the control of a ferredoxin promoter 139 (Figures 2 and S3) . When we introduced these plasmids sequentially, we failed to get any viable colonies 140 after introducing the second vector that harbors Cas9 coding sequence. Reasoning that the efficiency of 141 the second conjugation step could be the source of failure, we lengthened the donor/acceptor co-cultivation 142 step of the second conjugal transfer from 24 to 72 h; this optimized protocol yielded reproducible, high-143 efficiency mutations at multiple test loci (see Supplementary Text for a more detailed description of the 144 method's development). 145 146
Constructing mutants to validate Cs pathways in vitro 147
We used the Cas9-based genetic system to construct deletion mutants in each of the 10 pathways. 148
In each case, our repair template effected the removal of an 80-150 bp portion of the targeted gene in the 149
Cs chromosome (Figures 2B and S4) ; for simplicity, the resulting mutants (e.g., DporA(330-409)) are 150 6 referred to simply as DporA (see Table S4 for a list of deleted regions). We cultured each strain in vitro 151 and analyzed culture extracts by LC-MS or GC-MS (depending on the analyte), yielding the following 152 conclusions: (i) The production of each of the ten molecules is blocked by the corresponding pathway 153 mutant (Figures 3 and S5) , validating our prediction set; an important exception is detailed below in (iii). 154
(ii) Deleting one pathway does not appreciably alter the production of other molecules, indicating these 155 pathways function independently in vitro. (iii) Our predicted genetic locus for the branched short-chain fatty 156 acids (branched SCFAs) isobutyrate, 2-methylbutyrate, and isovalerate proved incorrect. In other 157 organisms (e.g., Streptomyces avermitilis (22)), the branched-chain a-ketoacid dehydrogenase complex 158 (BCKDH) converts branched-chain amino acids (BCAAs) into branched SCFAs. To our surprise, deletion 159 of the BCKDH gene CLOSPO_03305 did not affect branched SCFA production. To our surprise, the DporA 160 mutant -a gene we previously showed to be involved in the oxidative catabolism of aromatic amino acids 161 (10) -proved to be deficient in the production of all three branched SCFAs (Figure 3) . PorA is a member 162 of the pyruvate:ferredoxin oxidoreductase (PFOR) superfamily; like the BCKDH, PFOR enzymes are 163 thiamine-PP dependent, but they harbor an array of iron-sulfur clusters for electron transfer in place of 164 lipoate and flavin, and reduce ferredoxin or flavodoxin instead of NAD + (23). Although PFOR superfamily 165 members are known to utilize pyruvate in anaerobic bacteria (generating acetate), their utilization of 166 branched-chain a-keto acids derived from BCAAs constitutes a non-canonical pathway for branched SCFA 167 production, having only been observed in Archaea (24, 25) . We found multiple porA homologs in the 168 genomes of other human gut isolates that are highly transcribed in human stool metatranscriptomes, 169
suggesting that this pathway could be a substantial contributor to the host branched SCFA pool ( Figures  170   1, 3, and S2) . 171
172
In vivo modulation of microbiome-derived small molecules using Cs mutants 173
Having validated our target pathways in vitro, we set out to determine whether we could use these 174 mutants to "toggle" off the production of each pathway product in the context of host colonization. For this 175 experiment, we used a subset of five mutants. The first four were DcutC, DprdA, DcroA, and DhadB; for the 176 fifth, we took advantage of the markerless nature of our CRISPR-based genetic system to construct a 177
DporA/DhadB double mutant, with the goal of eliminating the production of all four branched SCFAs 178 (isobutyrate, 2-methylbutyrate, and isovalerate via DporA, and isocaproate via DhadB). We mono-179 colonized germ-free mice with WT Cs and the five mutants (Figure 1) ; after four weeks, we sacrificed the 180 mice and measured the concentration of each molecule in serum, urine, cecal contents, and fecal pellets. 181
We drew three observations from these data: 1) Each metabolite (or its host metabolic product) was 182 substantially reduced in the corresponding mutant (Figure 4) . 2) The WT/mutant differences were smaller 183 for isocaproate and butyrate due to a combination of two factors: low production by WT Cs relative to the 184 native level of each molecule (usually mM), and a background level of the metabolite in mutant-colonized 7 mice, possibly due to a source of contaminating molecule in the chow. 3) The WT/mutant difference was 186 especially large for the branched SCFAs isobutyrate, 2-methylbutyrate, and isovalerate, which form a pool 187 of >2 mM in the cecal contents of WT Cs-associated mice that falls to near-baseline in the DporA/DhadB-188 associated animals. Overall, these data validate the utility and generality of using Cs mutants to deplete 189 microbiome-derived molecules in the host, and they highlight that the presence of a pathway in an 190 organism can lead to production levels that vary from native to orders of magnitude below. Thus, the choice 191 of a producer organism that can support the biosynthesis of native metabolite levels depends on unknown 192 factors beyond the mere presence of a corresponding pathway. 193
194

Genetic control of microbiota metabolite production uncovers immune modulatory properties of 195
BSCFAs 196
In light of our ability to 'toggle' off the Cs-derived small molecules in vivo, we returned to our original 197 motivation for establishing the new genetic system: to study the role of microbiome-derived molecules in 198 mediating microbe-host interactions. We chose the branched SCFAs for two reasons: (i) Like the 199 conventional SCFAs acetate, propionate, and butyrate, they are highly abundant in the cecum and colon 200 (concentrations in the mM range) (26); but unlike the SCFAs, which are known to modulate the host 201 immune response via GPR41/43 (1), very little is known about the biology of the branched SCFAs. (ii) Cs 202 produces them robustly; they constitute a pool of >2 mM (Figure 4) . Hypothesizing that the branched 203 SCFAs -like conventional SCFAs -might modulate the host immune response, we colonized germ-free 204 mice with WT Cs and the DporA/DhadB mutant. After five weeks, we sacrificed the mice, isolated immune 205 cells from the small intestine and mesenteric lymph nodes, and analyzed them by mass cytometry. and DporA/DhadB-colonized mice were similar by broad metrics of immune function (e.g., total numbers of 207 CD4+ and CD8+ T cells, B cells, and innate immune cells; percentages of effector cell subpopulations; 208 cytokine levels). However, the DporA/DhadB-colonized mice had an increased number of immunoglobulin The hundreds of microbiome-derived molecules that accumulate in circulation represent one of the 216 most concrete modes of communication between the host and its microbiota. Remarkably little progress 217 has been made in systematically studying their effects on host biology, due in part to the absence of a 218 method that enables the selective depletion of one member of this pool. One approach to addressing this 219 challenge is to colonize germ-free mice with a wild-type gut bacterial species versus a metabolite-deficient 220 8 mutant. Given the outsize role of Clostridium and related anaerobic Firmicutes in generating this pool of 221 high-abundance metabolites, the lack of a reliable genetic system for commensal strains of Clostridium 222 has been a key impediment to generalizing this approach. The system we introduce here is a first step 223 toward that goal; it validates that genetics can be performed in a microbiome-derived Clostridium species 224 rapidly, reliably, and without the need for a marker, and it demonstrates the utility of WT/mutant pairs for 225 interrogating the host effects of microbiome-derived molecules. Given the versatility of Cas9, the key 226 factors for generalizing this system to other Clostridium species are the ability to get DNA into a strain and 227 the availability of replication origins for the plasmids that deliver the mutagenesis and repair elements. An 228 alternative strategy would be to deliver Cas9 and the gRNA as a purified ribonucleoprotein, forgoing the 229 need for plasmid-borne elements. Both strategies could expand the scope of Cas9-mediated mutagenesis 230 to important but previously inaccessible Firmicutes such as butyrate producers from Clostridium clusters 231 IV/XIVa (e.g., Faecalibacterium prausnitzii) (27), the bile acid metabolizers C. scindens and C. hylemonae 232 (28), and the leanness-associated bacterium Christensenella minuta (29). 233
Cs is a prolific producer of amino acid metabolites, and our in vitro studies show that we can 234 predictably block each pathway. However, one of the most striking observations is the difference in the 235 concentration of each pathway product in the context of host colonization. 5-aminovalerate, indole 236 propionate, isobutyrate, 2-methylbutyrate, isovalerate, propionate, and trimethylamine-N-oxide (TMAO) 237 are produced robustly in vivo whereas isocaproate and butyrate are generated at 10-100-fold below the 238 native concentration range. By highlighting that the mere presence of a pathway does not imply that it will 239 function robustly in the host, our data raise questions about computational approaches that predict 240 metabolic function based on gene or transcript levels (30, 31), and they suggest the importance of 241 understanding pathway regulation and substrate availability under conditions of colonization by a complex 242 native community. 243
The conventional SCFAs acetate, propionate, and butyrate modulate host immune function and 244 induce regulatory T cells via a pair of GPCRs, GPR41/43. Though they are also predominantly microbiome-245 derived and present at high concentration (26), much less is known about the branched SCFAs isobutyrate, 246 2-methylbutyrate, and isovalerate. Isovalerate was recently shown to be a ligand for Olfr558, a GPCR in 247 enterochromaffin cells that controls the secretion of serotonin (32). Our data uncover a novel role for the 248 branched SCFA pathway in modulating the production of IgA, the predominant mucosally secreted 249 antibody (33) whose mechanisms of microbiome modulation are an active area of study (34-36). In light of 250 the fact that the conventional SCFAs have been shown to exert the opposite effect -induction of IgA-251 producing B cells (37) -it will be of interest to determine the molecular mechanism by which the branched 252 The prefix "mgc" stands for "metabolic gene cluster". Genes that comprise each pathway are shown above 396 the corresponding arrows; the numbers indicate a locus tag suffix for Cs, where the prefix is "CLOSPO_". 397 Traces in red show the metabolite whose production is blocked by the mutation indicated at the beginning 414 of each row. Each mutant is deficient in the production of the corresponding pathway product, but proficient 415 in the production of all other pathway products. 416 
MATERIALS AND METHODS 30
Assessing the metagenomic abundance of each pathway 31
We used MetaQuery (1) to assess the metagenomic abundance of each pathway. We started by 32 identifying a key gene in each pathway -one that is predicted to encode an enzyme that catalyzes 33 essential or committed step: cutC (trimethylamine), prdA (5-aminovalerate), tdcA (tryptamine), fldB 34 (indolepropionate), porA (isovalerate, 2-methylbutryate, isobutyrate), hadB (isocaproate), talA 35 (propionate), and thlA (butyrate). We used the following parameters in Metaquery: pairwise identity >50%, 36 maximum e-value: 1e-5, query and target alignment coverage >70%, across 2000 publicly available human 37 metagenomic stool samples. The results are shown in Figure S2 . 38
39
Assessing the metatranscriptomic abundance of each pathway 40
We built a local DNA sequence database that consists of 479 bacterial reference genomes obtained 41 from the NIH Human Microbiome Project (HMP) website (https://hmpdacc.org/). We used the amino acid 42 sequences of CutC, PrdA, TdcA, FldB, PorA, HadB, TalA, and ThlA as queries in a tblastn search of this 43 database to identity homologs of each enzyme (maximum E-value: 1e-5). After removing hits with 44 coverage <50% or pairwise identity <40%, we used the remaining sequences to construct a local database 45 for metatranscriptomic analysis. We mapped metatranscriptomic reads from the stool of nine healthy 46 human subjects (2) to this database using Bowtie 2 (local, medium sensitivity); representative mapping 47 results are shown in Figure S2 . We then set out to compare the expression of our target genes with its 48 surrounding neighbors in the genome. For any gene to which reads mapped, we extracted a genomic 49 region of ~100 kb (~50 kb 5' of the gene and ~50kb 3') to construct a second database. The same 50 metatranscriptomic dataset was mapped to this database using Bowtie 2 (local, medium sensitivity); 51 representative results for two clusters, prd and por, are shown in Figure S2 . 52
53
Constructing Cs mutants using CRISPR/Cas9 54
Vector assembly 55
Primers and strains used in this study are listed in Tables S1 and S2, respectively. The coding 56 sequence of Cas9 was cloned from the vector pMJ825 (Addgene) using primers 57 83153_Cas9_(A10D)_XbaI_F and 83153_Cas9_XhoI_R. The purified PCR product and pMTL83153 were 58 digested with XbaI/XhoI and ligated together using Instant Sticky-end Ligase (NEB), yielding 59 pMTL83153_fdx_Cas9 (plasmid 1, P1) (Figures 2 and S3) . The sequences highlighted in green are homologous to regions in pMTL82254. The sequence in blue is a 72 synthetic promoter predicted by PePPER using the Clostridium sporogenes ATCC 15579 (Cs) genome as 73 the calculation input (3). The red sequence is a small guide RNA (sgRNA) targeting the Cs chromosome. 74
The sequence in yellow is for Cas9 binding, and the pink sequence is a terminator region obtained from 75 the Cs 16s rRNA gene (CLOSPO_00916). The underlined sequences are NotI restriction sites that were 76 not used in this study. 77
Using the cutC gene as an example, we used two primer pairs, 02864_TMA_F1+R2 and 78 02864_TMA_F3+R4 (Table S1), to synthesize the repair template, which consists of two regions (700-79 1200 bp each) flanking the sequence that is targeted for excision. The gRNA locus was synthesized 80 commercially (gBlocks, IDT). The synthetic gRNA locus was fused to the repair template using fusion PCR 81 with the primer set gRNA_F_NotI + gRNA_R_AscI. The purified PCR product (consisting of gRNA locus + 82 repair template) was then cloned into a pMTL82254 backbone (4) that had been doubly digested by 83 NotI/AscI using Instant Sticky-end Ligase (NEB), yielding pMTL82254_TMA_gRNA+rep temp (plasmid 2, 84 P2) (Figures 2 and S3 ). P1 and P2 (Figure S3 ) were introduced into two separate strains of E. coli S17 85 by electroporation. 86 87
Introducing vectors by conjugation into Cs 88
The process of constructing a single Cs mutant consists of two sequential conjugations from E. coli 89 into Cs. For the first conjugation, a single colony of wild-type Cs was used to inoculate a 2 ml TYG broth 90 culture in an anaerobic chamber at 37 °C under an atmosphere consisting of 10% CO2, 5% H2, 85% N2. 91 E. coli S17 harboring P2 was grown in LB broth supplemented with erythromycin (250 µg/mL) at 30 °C 92 with shaking at 225 rpm. After 17-24 hours, 1 mL E. coli S17 culture was centrifuged at 1000 x g for 1 min. 93
The supernatant was discarded and the cell pellet was washed twice with 500 µL PBS buffer (pH = 7.2). 94
The washed E. coli cell pellet was transferred into the anaerobic chamber, and 250 µL of Cs overnight 95 culture was added and thoroughly mixed with E. coli cell pellet by pipetting. A 30 µL aliquot of the cell 96 mixture was plated on a pre-reduced TYG agar plate as a liquid dot (a total of eight dots) for 24 h. Cell 97 material in these dots was removed from the plate using a sterile inoculation loop and suspended in 250 98 µL pre-reduced PBS buffer (pH = 7.2). 100 µL of the cell suspension was plated on TYG agar + 10 µg/mL 99 4 erythromycin + 250 µg/mL D-cycloserine. Cs colonies typically appeared after 36-48 h. Three colonies 100 were picked and re-streaked on TYG agar + 10 µg/mL erythromycin + 250 µg/mL D-cycloserine to isolate 101 single colonies. The transformation efficiency was typically high for this step, so one single colony was 102 picked as the starting point for the second conjugation. 103
In the second conjugation, E. coli S17 harboring P1 was grown in LB broth supplemented with 104 chloramphenicol (25 µg/mL) at 30 °C with shaking at 225 rpm. After washing the E. coli cell pellet as 105 described in the previous paragraph, the washed E. coli cell pellet was transferred into anaerobic chamber 106 and 250 µL of an overnight culture Cs (harboring vector P2) was added and thoroughly mixed with the E. 107 coli cell pellet by pipetting. A 30 µL aliquot of the cell mixture was plated on a pre-reduced TYG agar plate 108 as a liquid dot (a total of eight dots) for 72 h. Cell material in these dots was removed from the plate using 109 a sterile inoculation loop and suspended in 250 µL pre-reduced PBS buffer (pH = 7.2). 100 µL of the cell 110 suspension was plated on each of two TYG plates with 10 µg/mL erythromycin + 15 µg/mL thiamphenicol 111 + 250 µg/mL D-cycloserine. Cs colonies typically appeared after 36-48 h. Sixteen colonies were picked 112 and re-streaked on TYG agar + 10 µg/mL erythromycin + 15 µg/mL thiamphenicol + 250 µg/mL D-113 cycloserine to isolate single colonies. The isolated single colony was used to inoculate TYG broth 114 supplemented with 10 µg/mL erythromycin + 15µg/mL thiamphenicol, and genomic DNA was isolated from 115 the resulting cell material using Quick DNA fungal/bacterial kit (Zymo Research). We used diagnostic PCR 116 and sequencing to identify mutants whose genomes harbor the desired deletions (see Figure S4 for more 117 details). For generating double-deletion mutants like ΔporA/ΔhadB, the first deletion was introduced using 118 the CRISPR/Cas9 system. Following sequence verification, the mutant was plated on non-selective agar 119 for multiple rounds to cure both plasmids, and then the process was repeated to introduce a second 120 deletion. 121
122
LC-MS/GC-MS analysis of Cs metabolites 123
A single colony of wild-type Cs or one of the mutant strains described herein was used to inoculate 124 a 1 mL pre-reduced TYG broth culture [500 mL: 15 g tryptone, 10 g yeast extract, 0.5 g sodium 125 thioglycolate, antibiotic concentration (if needed): thiamphenicol, 15 µg/ml; erythromycin, 10 µg/ml]. To 126 pre-reduce, the TYG medium was left in the chamber with a loosened cap for at least 48 h before 127 inoculation. The culture was incubated in an anaerobic chamber at 37 °C under an atmosphere consisting 128 of 10% CO2, 5% H2, 85% N2. 129 (10 µL 10 mM n-valeric acid in water as internal standard, 50 µL 6M HCl, 190 µL ddH2O, 250 µL diethyl 195 ether) and six 6 mm ceramic beads were added to ~100 mg wet cecal contents or fecal pellets. Samples 196 temperature. Cells were washed twice in PBS + 0.5% BSA + 0.02% NaN3 and stored at -80 ˚C for 239 subsequent mass cytometry analysis. 240 241
1) Quantification of the conversion of d9-choline to d9-trimethylamine (d9-TMA) by wild-type and
Mass cytometry analysis 242
Antibody preparation: A summary of all mass cytometry antibodies, reporter isotopes and 243 concentrations used for analysis can be found in Table S3 . Primary conjugates of mass cytometry 244 antibodies were prepared using the MaxPAR antibody conjugation kit (Fluidigm) according to the 245 manufacturer's recommended protocol. Following labeling, antibodies were diluted in Candor PBS 246 Antibody Stabilization solution (Candor Bioscience GmbH, Wangen, Germany) supplemented with 0.02% 247 NaN3 to between 0.1 and 0.3 mg/mL and stored long-term at 4 °C. Each antibody clone and lot was titrated 248 to optimal staining concentrations using primary murine samples. One antibody cocktail was prepared for 249 the staining of all samples for mass cytometry analysis. 250
Mass-Tag Cellular Barcoding: Mass-tag cellular barcoding was pre-formed as previously described 251 (9). Briefly, 1*10 6 cells from each animal were barcoded with distinct combinations of stable Pd isotopes 252 in 0.02% saponin in PBS. All samples were barcoded together. Cells were washed two times in PBS with 253 0.5% BSA and 0.02% NaN3 and pooled into a single tube. After data collection, each condition was 254 deconvoluted using a single-cell debarcoding algorithm (9). 255
Mass Cytometry Staining and Measurement: Cells were resuspended in PBS with 0.5% BSA and 256 0.02% NaN3 and unlabeled antibodies against CD16/32 were added at 20 μg/ml for 5 min at RT on a 257 shaker to block Fc receptors. Surface marker antibodies were then added, yielding a 500 µL final reaction 258 volume and stained at room temperature for 30 min at RT on a shaker. Following staining, cells were 259 washed once with PBS with 0.5% BSA and 0.02% NaN3 then once with 1X Foxp3/Transcription factor 260 permeabilization buffer (eBioscience). Cells were then stained with intracellular antibodies in a final volume 261 of 500 μL permeabilization buffer for 30 min at RT on a shaker. Cells were washed twice in PBS with 0.5% 262 BSA and 0.02% NaN3 and then stained with 1 mL of 1:4000 191/193 Ir DNA intercalator (Fluidigm) diluted in 263 PBS with 1.6% PFA overnight. Cells were then washed once with PBS with 0.5% BSA and 0.02% NaN3 264 and then two times with double-deionized (dd)H2O. Care was taken to assure buffers preceding analysis 265
were not contaminated with metals in the mass range above 100 Da. Mass cytometry samples were diluted 266 in ddH2O containing bead standards (see below) to approximately 10 6 cells per mL and then analyzed on 267 a CyTOF TM 2 mass cytometer (Fluidigm) equilibrated with ddH2O. We analyzed 2-6*10 5 cells per animal, 268 consistent with generally accepted practices in the field. 269
Bead Standard Data Normalization: Just before analysis, the stained and intercalated cell pellet 270 was resuspended in ddH2O containing the bead standard at a concentration ranging between 1 and 2*10 4 271 beads per ml as previously described (10). The bead standards were prepared immediately before 272 analysis, and the mixture of beads and cells were filtered through a filter cap FACS tubes (BD Biosciences) 273 9 before analysis. All mass cytometry files were normalized together using the mass cytometry data 274 normalization algorithm (10), which uses the intensity values of a sliding window of these bead standards 275 to correct for instrument fluctuations over time and between samples. 276
277
SUPPLEMENTARY TEXT 278
Developing a CRISPR/Cas9-based genetic system for Cs: Optimization and experimental design 279
We started by testing the CRISPR-Cas9 nickase system in Cs, as a similar system had been 280 developed for C. cellulolyticum, a candidate for organic solvent production in industry (11). We assembled 281 the Cas9 nickase, the small guide RNA (sgRNA), and a ~2 kb repair template that flanks the targeted 282 region in the Cs chromosome with pMTL83153 (4). We sequenced the Cs transconjugant and found no 283 evidence of genome editing, leading us to try a genetic system with a fully functional Cas9 enzyme. 284
However, after replacing the Cas9 nickase with wild-type Cas9 in the assembled vector, we were 285 unable to obtain any viable colonies that harbor the modified vector even after multiple trials. Since 286 previous literature suggests that delayed or inducible Cas9 expression (12, 13) can improve genome 287 editing efficiency, we put Cas9 under the control of either a spoIIE promoter or a lactose-inducible 288 promoter. We still did not obtain any viable colonies with the resulting vectors. 289
In the meantime, we observed that we were unable to get viable colonies of Cs when the size of 290 the conjugal vector exceeds ~10 kb. To address this problem, we divided the components of the CRISPR-291
Cas9 system (Cas9 enzyme, gRNA, and repair template) between two separate vectors (Figure S3) . 292
However, we still failed to get viable colonies. By extending the incubation time of Cs with the E. coli 293 conjugation donor to 72 h during conjugation, we were able to get one viable colony. Based on this 294 observation, we developed an efficient protocol for mutating genes in Cs using CRISPR-Cas9 (See 295
Materials and Methods for details). The key gene in each pathway -one that is predicted to encode an enzyme that catalyzes essential or 307 committed step -was examined by MetaQuery to assess its metagenomic abundance across >2000 public 308 available human stool metagenomes. (B-C) Representative results of metatranscriptomic analyses of 309 12 MGCs and their homologs in this study. SRR8489XX indicates the accession number of each healthy 310 human stool metatranscriptomic dataset examined in this study. For example, Figure S2B, 1a shows that 311 454 reads from the metatranscriptomic sample of human subject SRR848946 mapped to the prd cluster 312 in D. longicatena DSM13814. This cluster is highly transcribed compared to the surrounding genes in the 313 D. longicatena genome (Figure S2B, 1b) . Figure S4 . The scheme for diagnostic PCR used in this study and the sequencing result of three cutC 320 mutants compared to wild-type Cs. The primer set DiagF+DiagR is used to amplify a sequence from the 321 candidate mutants that carry both pMTL83153_fdx_Cas9 and pMTL82254_gRNA_rep Temp (Figure S3) . 322
The amplicons were then sequenced using the primer SeqF and compared to the sequence of WT Cs to 323 determine whether the 80 bp sequence (in red) has been deleted in the mutant. 
